Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Wirksamkeitsstudie zur chirurgischen Entfernung von Vorhofflimmern (SAFE)

2. Oktober 2026 aktualisiert von: Richard Whitlock, Population Health Research Institute

SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Atrial fibrillation (AF) affects more than 1% of the general population and is an important risk factor for stroke. AF prevalence increases with age, occurring in 10 to 15% of patients older than 80 years of age, which is important with the aging population. Of patients undergoing cardiac surgery, 10.8% have a history of AF. AF is believed to cause the left atrium to dilate and lose its transport function. AF significantly increases the risk of ischemic stroke of cardioembolic origin, but is also associated with heart failure and impairs quality of life. Although the causal relationship between the 2 clinical entities has not been fully elucidated, AF is believed to cause heart failure via several mechanisms.

Ablation of AF is the application of scars to the atrial tissue to disrupt faulty electrical signals that cause the arrhythmia. If surgical ablation of AF yields a benefit similar to catheter-based AF ablation, thousands of people undergoing cardiac surgery could benefit from this procedure each year. SAFE will be a landmark trial in cardiac surgery, definitely establishing surgical AF ablation's impact on cardiovascular outcomes. Cardiac surgery is the optimal setting to establish whether maintenance of sinus rhythm through AF ablation yields clinical benefit, and is a setting where sham-control is possible. This will not only provide evidence for the cardiac surgical patients but will bolster the evidence for ablation (catheter or stand-alone surgical) in other AF patients.

The intervention under investigation is concomitant surgical AF ablation which is compared to no surgical AF ablation. The primary outcome is hospital readmissions with heart failure during 4 years of follow-up. This study will enroll 2000 patients from 50 centres, globally. Patients will be followed at hospital discharge, 4 to 6 weeks after surgery, 6 months after surgery, and then at 6-month intervals until the final follow-up visit, for a median follow-up for 4 years.

Studientyp

Interventionell

Einschreibung (Geschätzt)

2000

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Ontario
      • Hamilton, Ontario, Kanada, L8L 2X2
        • Rekrutierung
        • Hamilton General Hospital
        • Kontakt:
        • Hauptermittler:
          • Richard Whitlock, MD MSc FRCSC

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age ≥ 18 years;
  • Undergoing a clinically indicated cardiac surgical procedure: CABG, AVR, ascending aorta replacement, or combinations thereof;
  • Documented history of paroxysmal or persistent AF
  • Provide informed consent

Exclusion Criteria:

  • Dominant atrial arrhythmia is atrial flutter;

  • Documented left atrial diameter ≥ 6 cm;

  • Previous cardiac surgery requiring opening of the pericardium;

  • Patients undergoing any of the following procedures:

    1. Heart transplant
    2. Complex congenital heart surgery
    3. Sole indication for surgery is ventricular assist device insertion
    4. Mitral valve repair or replacement
    5. Tricuspid valve repair or replacement
  • Patient resides in a long-term care facility

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Surgical Atrial Fibrillation Ablation Group

Surgeon will perform left atrial ablation during patient's cardiac surgery procedure.

Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.

Kein Eingriff: No Surgical Atrial Fibrillation Ablation Group

Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of hospital readmissions for heart failure over duration of follow-up
Zeitfenster: Common termination point for trial (median follow-up of 4 years)

Total number of hospital readmissions for heart failure.

Common termination point for trial (median follow-up of 4 years)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up
Zeitfenster: Common termination point for trial (median follow-up of 4 years)

Number of Ischemic stroke or systemic arterial embolism events over duration of follow up

Common termination point for trial (median follow-up of 4 years)
Length of ICU stay
Zeitfenster: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

Length of ICU stay, including readmissions, from study intervention surgery to hospital discharge, including readmissions

From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
Length of hospital stay
Zeitfenster: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

Length of hospital stay

From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
Freedom from recurrence of atrial tachyarrhythmia
Zeitfenster: 1 year post-operatively

Freedom from recurrence of atrial tachyarrhythmia

1 year post-operatively
Number of days free from admission to healthcare facility or presentation to the emergency department for heart failure
Zeitfenster: Common termination point for trial (median follow-up of 4 years)

Number of days free admission to healthcare facility or presentation to the emergency department for heart failure

Common termination point for trial (median follow-up of 4 years)
All-cause mortality
Zeitfenster: Common termination point for trial (median follow-up of 4 years)

All-cause mortality

Common termination point for trial (median follow-up of 4 years)
Cardiovascular mortality
Zeitfenster: Common termination point for trial (median follow-up of 4 years)

Cardiovascular mortality

Common termination point for trial (median follow-up of 4 years)
Antiarrhythmic drug use
Zeitfenster: Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)

Antiarrhythmic drug use

Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)
Number of patients undergoing atrial fibrillation ablation
Zeitfenster: 90 days post- study surgery until common termination point for trial (median follow-up of 4 years)

Number of patients undergoing atrial fibrillation ablation

90 days post- study surgery until common termination point for trial (median follow-up of 4 years)
Quality of Life - atrial fibrillation specific
Zeitfenster: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Atrial fibrillation specific quality of life as assessed by the Atrial Fibrillation Effect on QualiTy of Life questionnaire (AFEQT) which is 20 questions using a 7 point Likert scale where a higher score means a worse outcome.

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Quality of Life - heart failure specific
Zeitfenster: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Heart failure specific quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) which is a 12 questions using Likert scales where a higher score is a better outcome.

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Quality of Life - General
Zeitfenster: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Quality of life- general as assessed by the European quality of life index version 5D (EQ-5D-5L) which consists of a descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

At 1 year, and at common termination point for trial (median follow-up of 4 years)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Ischemic stroke and systemic arterial embolism
Zeitfenster: Up to 30 days post-operatively

Safety outcome

Up to 30 days post-operatively
Number of patients requiring permanent pacemaker implantation
Zeitfenster: Up to 1 year post-operatively

Safety outcome

Up to 1 year post-operatively
Volume of chest tube output
Zeitfenster: Up to 24 hours post-operatively

Safety outcome - chest tube output measured in mL.

Up to 24 hours post-operatively
Re-operation for bleeding
Zeitfenster: From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

Safety outcome

From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
All-cause mortality
Zeitfenster: Prior to discharge or within 30 days post-operatively (whichever occurs first)

Safety outcome

Prior to discharge or within 30 days post-operatively (whichever occurs first)
Post-operative major bleeding
Zeitfenster: <48 hours after surgery

Safety outcome

<48 hours after surgery
Number of patients with pulmonary vein stenosis
Zeitfenster: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Safety outcome

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Number of patients with stiff left atrium syndrome
Zeitfenster: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Safety outcome

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Number of patients with esophageal to atrial fistula
Zeitfenster: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Safety outcome

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Health economic analysis of surgical atrial fibrillation
Zeitfenster: At 1 year, and at common termination point (median follow-up of 4 years)

Economic analysis will be assessed via health care utilization by patients

At 1 year, and at common termination point (median follow-up of 4 years)
Health economic analysis of surgical atrial fibrillation
Zeitfenster: At 1 year, and at common termination point (median follow-up of 4 years)

Economic analysis will be assessed via a questionnaire of health care visits and costs incurred by patients.

At 1 year, and at common termination point (median follow-up of 4 years)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Richard Whitlock, Population Health Research Institute
  • Hauptermittler: Emilie Belley-Côté, Population Health Research Institute

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Juni 2023

Primärer Abschluss (Geschätzt)

30. September 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

4. Mai 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. Juni 2022

Zuerst gepostet (Tatsächlich)

28. Juni 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • SAFEV1.0

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .